|Bid||13.75 x 1100|
|Ask||23.66 x 1300|
|Day's Range||14.62 - 16.25|
|52 Week Range||7.67 - 47.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.00|
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the European Commission ("EC"), based on a positive opinion issued by the European Medicines Agency ("EMA"), has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the second quarter of 2022 and provided an update on recent corporate highlights.